Effects of a novel histamine H2-receptor antagonist, lafutidine, on the mucus barrier of human gastric mucosa
| Autor: | Kyoko Hotta, Hiroyoshi Ota, Kazuhiko Ishihara, Fukuto Maruta, Tomoaki Ikezawa, Atsushi Sugiyama, Takafumi Ichikawa |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Pyridines Administration Oral Severity of Illness Index Gastroenterology Lafutidine chemistry.chemical_compound Piperidines Stomach Neoplasms Internal medicine Acetamides medicine Gastric mucosa Humans Aged Hepatology business.industry Mucin Antagonist Middle Aged Anti-Ulcer Agents Mucus Treatment Outcome medicine.anatomical_structure Histamine H2 Antagonists chemistry Gastric Mucosa Gastritis Immunohistochemistry Female medicine.symptom business Histamine |
| Zdroj: | Journal of Gastroenterology and Hepatology. 22:1800-1805 |
| ISSN: | 1440-1746 0815-9319 |
| Popis: | Background and Aim: Lafutidine is a novel histamine H2-receptor antagonist used primarily as an antisecretory agent in Japan. Previous human studies have not assessed its gastroprotective effects. The purpose of the present study was to determine the effects of lafutidine on the human gastric mucus layer using both histological and biochemical methods. Methods: Of the 14 patients scheduled for gastrectomy who consented to participate, seven were given 14 days of lafutidine 20 mg/day (lafutidine group) and the others received no medication (control group). The surface mucus gel layer in Carnoy-fixed tissue sections was examined immunohistochemically. Both the thickness of the mucus layer and its mucin content were measured in gastric corpus mucosa. Results: There was no detectable difference between the groups in the grade of gastritis or the immunohistochemical staining characteristics. The laminated structure of the surface mucus gel layer was retained after administration of lafutidine and it was thicker than the layer in the control group. The surface layer in the lafutidine group had three-fold more mucin than that in the control group. There was no difference between the two groups in the mucin content of the deep mucosa. Conclusion: Lafutidine, given at clinical dosages, not only inhibits acid secretion but also strengthens the mucus barrier of the human gastric mucosa. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text